Replies to post #212751 on Amarin Corp Plc (AMRN)

[Atom0aks]

Again, 4.8% OF WHAT / HOW MANY?

4.8% of people who experience a primary efficacy end point,

The primary efficacy end point was a composite of cardiovascular death, nonfatal myocardial infarction (including silent myocardial infarction), nonfatal stroke, coronary revascularization, or unstable angina in a time-to-event analysis.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1812792

I'm really not sure how I can simplify this concept further for you...